CBO Finds Net Prices for Brand Name Drugs More Than Doubled from 2009-2018; HHS Finds More Than Five Million Beneficiaries Struggled to Afford Prescriptions in 2019 Two government reports released this week underscore the urgency for action to reign in out-of-control prescription drug prices by holding Big Pharma accountable. A report released Wednesday from the
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for Active Ingredients or New Molecules A new analysis published this week in Nature Biotechnology further reveals how the…
DECISION WILL HELP PROTECT SENIORS, TAXPAYERS AND THE U.S. HEALTH SYSTEM FROM EGREGIOUS PRICING ON AN UNPROVEN TREATMENT For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected]…
Next FDA Commissioner Must Promote Competition, Transparency And Value In The Pharmaceutical Marketplace For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington,…
Biogen Decision to Change Aduhelm Price After Public Outcry Demonstrates Big Pharma Prices Solely Designed to Maximize Profits During a recent interview at the J.P.
Brand Name Drug Companies’ Business-as-Usual Approach to Price Increases Highlights Urgency for Congress to Hold the Industry Accountable In case you missed it…
Fourth Major Round Of Pandemic Price Hikes Highlight Urgency for Policymakers to Hold Big Pharma Accountable For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington,…
Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch Prices Despite unprecedented attention on the crisis of prescription drug affordability…
Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite unprecedented attention on the crisis of prescription drug affordability, Big Pharma maintained the industry’s…
Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual Despite unprecedented attention on the crisis of prescription drug affordability…